Company Summary - Fusion IP PLC (LSE:FIP)
62.00p
1.50p
(-2.42%)
Financial ServicesMarket cap: £45.138m
NEW Explore our new and improved report for Fusion IP PLC >>
Gain access to various premium features such as detailed information on financial reports, broker forecasts, directors and shareholders information.
Summary
Commercialisation of intellectual property
| Financials - Annual Report (31/07/2011) | ||
|---|---|---|
| Turnover | £m | 0.98 |
| Pre-tax Profit | £m | 1.05 |
| EPS | p | -0.53 |
| DPS | p | - |
| Dividend Yield | % | |
| Director | Board Role |
|---|---|
| Douglas Liversidge | Chairman |
| David Baynes | Chief Executive |
| Tony Gardiner | Finance Director |
Products Brands & Subsidiaries
Products & Brands
There are no products for this company.
Subsidiaries
Diurnal Ltd; Phase Focus Ltd; Absynth Biologics Ltd; Medella Therapeutics Ltd; Fusion IP Cardiff Ltd; Fusion IP Sheffield Ltd
Broker Sentiment (1 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Asalus - Funding | 09/02/2012 |
| Mesuro - Sales | 02/02/2012 |
| Seren - commercial agreement | 01/02/2012 |
For more information
and investor relations, visit the
Fusion IP PLC company website: